home.aspx
 
EVENTS

2nd Middle East Pharmacy and Pharmaceutical Conference
2ND MIDDLE EAST PHARMACY AND PHARMACEUTICAL CONFERENCE
December 09-10, 2019
The 2nd Middle east Pharmacy and Pharmaceutical Conference will be held amid December 09-10, 2019 at Dubai, UAE.  Pharma Conference 2019 is a worldwide stage for drug specialists, pharmaceutical advertising professional's, pharmaceutical industry experts, and analysts, researchers, clinicia...

SiriusDecisions 2019 Technology Exchange
SIRIUSDECISIONS 2019 TECHNOLOGY EXCHANGE
December 09-11, 2019
The drive for growth never ceases for b-to-b organizations, and more than ever technology is at the centre of enabling that progress. Gone are the days however when a disparate, disconnected set of platforms strewn across sales, marketing an product can serve the organization effectively. An aligned...

CHEMO operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of value-adding active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, for human and animal health. While the main offices are located in Madrid, Lugano, Buenos Aires, CHEMO is acting worldwide, creating a broad and balanced manufacturing and commercial network across Europe, America, Asia and Africa, to address global opportunities and customers` needs in all major pharmaceutical markets.

RELATED NEWS


One of the major obstacles in the treatment of pancreatic cancer is the defense wall that is formed around the tumor. This "desmoplastic stroma" prevents chemotherapy from reaching the tumor. Scientists of the University of Twente now found out which part of the stroma can best be attacked. Furthermore, they discovered a peptide than can serve as an attacker. In "Science Advances' they show that using the combination of the peptide and the cytostatics, tumor volume can be dras...

READ MORE

Cancer of the pancreas is a particularly deadly cancer, claiming over 90 Precent of its victims within 5 years from diagnosis. It resists most standard therapies, including surgery, chemotherapy, radiation therapy, immunotherapy and targeted therapy, and metastasizes early, often before being diagnosed. A cure is possible only with very localized tumors. Now, however, a new cannabis-derivative called FBL-03G, loaded into tumor-targeted smart radiotherapy biomaterials systems (SRBs systems), show...

READ MORE

AstraZeneca has announced that its combination of Imfinzi durvalumab and tremelimumab has failed to hit its key target in a late-stage trial assessing its potential in patients with late-stage lung cancer. The drug giant reported that in the primary analysis population - patients with stage IV non-small cell lung cancer NSCLC whose blood TMB was 20 or more mutations per megabase - the combination did not meet the primary endpoint of improving overall survival (OS) compared to standard of care (S...

READ MORE

Bristol-Myers Squibb is out to expand the pool of colorectal cancer patients it can treat with Opdivo and its bringing in Bayer to help. The two companies, along with Bristol partner Ono Pharmaceutical, have joined forces in a clinical pact to test the immuno-oncology star alongside Bayers Stivarga in patients with microsatellite stable metastatic colorectal cancer, which represents about 95% of cases. The companies stayed tight-lipped on the collaboration’s terms, but they did note that t...

READ MORE

British pharmaceuticals giant Glaxosmithkline reported progress this morning on a drug it bought last year in a controversial 5.1bn dollars (4bn) deal. Zejula, a cancer treatment, met its primary target in a phase III trial, the company said. It means that women suffering from ovarian cancer who were given the drug increased their chances of progression-free survival. This means they continued to live with the disease, without it becoming worse. It happened regardless of their biomarker status &...

READ MORE

Uveal melanoma is a very aggressive type of melanoma that affects the eye. It is a rare disorder, affecting an estimated 2,500 people in the United States each year. However, nearly half of uveal melanoma patients will develop metastatic disease that migrates to other part of the body, primarily the liver. The prognosis for patients with metastatic uveal melanoma is very poor, with median survival of only 17 to 20 months. Researchers in Moffitt Cancer Center's Donald A. Adam Melanoma and Ski...

READ MORE

Roche is heading for EU approval of Tecentriq as first-line therapy for triple-negative breast cancer (TNBC), ahead of its checkpoint inhibitor rivals. The Committee for Medicinal Products for Human Use (CHMP) backed the use of the PD-L1 inhibitor in patients with locally-advanced or metastatic TNBC that cannot be treated with surgery and who haven’t previously received chemotherapy. The EMA typically approves drugs a few weeks after a positive CHMP opinion. The new indication – whic...

READ MORE

The US Food and Drug Administration (FDA) has accepted Glaxo Smith Klines application for Zejula (niraparib) in late stage ovarian cancer with priority review. The company announced that Tesaro, an oncology-focused business acquired by GSK, submitted a supplemental New Drug Application (sNDA) to the governing body, with an expected action date of 24 October 2019. The sNDA supports a potential new indication for the treatment in advanced ovarian, fallopian tube, or primary peritoneal cancer patie...

READ MORE

GlaxoSmithKline has been working to restrengthen in cancer, particularly through a multibillion-dollar purchase of Tesaro. The main drug from the buyout, Zejula, is now up for a priority review in late-stage ovarian cancer, where it's working to pick up a niche nod its rivals don't have. The FDA has accepted GSK's application for the drug to treat patients with advanced ovarian, fallopian tube or primary peritoneal cancer who have had at least three prior chemo regimens. The patients...

READ MORE

The U.S. FDA compiles a list of off-patent drugs without an approved generic to encourage the development of copycats. Now, the Chinese authorities are rolling out a similar initiative, only with some extra incentives. On Thursday, China’s National Health Commission published (Chinese) its first proposed list of 34 drugs (full list below) that the agency says are already off patent or nearing patent expiration but have no generic drug application in the country or lack competition. The pla...

READ MORE

EVENTS

2nd Middle East Pharmacy and Pharmaceutical Conference
2ND MIDDLE EAST PHARMACY AND PHARMACEUTICAL CONFERENCE
December 09-10, 2019
The 2nd Middle east Pharmacy and Pharmaceutical Conference will be held amid December 09-10, 2019 at Dubai, UAE.  Pharma Conference 2019 is a worldwide stage for drug specialists, pharmaceutical advertising professional's, pharmaceutical industry experts, and analysts, researchers, clinicia...

eyeforpharma Awards 2019
EYEFORPHARMA AWARDS 2019
December 11-11, 2019
You’ll already know if you’re a winner: your patients are telling you. But now it’s time to be recognised by your peers and the wider healthcare community. The eyeforpharma awards are unique. They’re the only awards that focus exclusively on what matters - value for patients ...